- The Myeloma Beacon - https://myelomabeacon.org -
ACE-011 (sotatercept)
By: Alyssa Liguori; Published: December 26, 2009 @ 5:24 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | sotatercept |
| Code Name: | ACE-011 |
| Company: | Celgene and Acceleron Pharma |
| FDA Clinical Phase: | 2 |
Description:
ACE-011 is a human fusion protein from the combination of Activin Receptor Type IIA and an antibody molecule. It is called a fusion protein because scientists have joined two different genes, each of which typically code for separate proteins. By fusing the genes, a new, unique protein is created with certain functions from both of the original proteins. This fusion protein, ACE-011, inhibits bone loss and promotes bone formation.
Clinical Trials:
For a list of clinical trials studying ACE-011 for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Web site for ACE-011: http://www.acceleronpharma.com [2].
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/12/26/ace-011/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=ACE-011&recr=&rslt=&type=&cond=myeloma&intr=&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
[2] http://www.acceleronpharma.com: http://www.acceleronpharma.com/content/products/ace-011.jsp
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.